HUAPONT PHARM.

INFORMATION CENTER

21

2020

-

07

关于阿斯利康阿那曲唑相关专利无效的公告

Author:


    2019年4月阿斯利康向苏州市中级人民法院起诉华邦制药“侵害发明专利权纠纷”,提出我司产品阿那曲唑片(瑞婷)侵犯该公司第02824544.X号发明专利(阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途)。

    我司认为,该专利存在创造性和新颖性的缺陷,于是向国家知识产权局专利复审委提交专利无效宣告请求书。国家专利复审委经过审查,认定该专利不具备创造性,于2020年4月1日做出第43778号无效宣告请求审查决定书,宣告该项发明专利(ZL02824544.X)全部无效。

    由于该发明已不具备专利效力,故江苏省苏州市中级人民法院于2020年5月18日做出判决((2019)苏05知初334号之一),对阿斯利康公司就我司阿那曲唑专利侵权一案予以驳回。

    故我司阿那曲唑片说明书所批适应症第二条用于绝经后妇女雌激素阳性的早乳腺癌的辅助治疗”合法合规不存在专利侵权。

    特此公告!

                                  

 

重庆华邦制药有限公司

                                 二O二O年七月二十一日

Latest News

2022-09-20

A new base of Huapont was officially completed and put into use

On September 19, 2022, the completion and commissioning ceremony of a new base was held, the new base is located in Changshou District, Chongqing. The construction of Changshou Base started on October 8, 2019, after 2 years and 11 months of construction, the total construction area 89036.79㎡ was completed, including four buildings for API, four buildings for storage warehouses, one building fro QC, one power center and one sewage treatment station. All plants are operated by gravity flow and equipped with automatic control systems such as DCS, SIS, BMS and WMS.

2022-05-31

Huapont Pharma was awarded the 2021 Outstanding Company for National Adverse Drug Reaction Monitoring and Evaluation

The National Adverse Drug Reaction Monitoring Center commended Huapont Pharm. Due to its outstanding for performing the main responsibility. Meanwhile, Huapont Pharm. is also the only pharmaceutical manufacturer in Chongqing that has been commended. Under the leadership of the Drug Safety Committee

2022-03-03

Huapont passed the NMPA GMP inspection for large-scale injection

From February 22 to February 25, 2022, and from March 1 to March 4, 2022, NMPA (National Medical Products Administration), Chongqing conducted on-site inspection for large-volume injection. The officers conducted a comprehensive inspection. including the R&D area and production site of the injection solution, specifically, the quality management and control at the site,

2021-12-29

Huapont Pharm. won the title of "Green Factory"

Huapont Pharm. was successfully approved as a municipal green factory recently by Chongqing Municipal Economic and Information Commission It is the recognition of the company's green development, healthy development and sustainable development. Huapont Pharm. Will always focus on the concept of green development, adhere to green manufacturing, vigorously promote our company's development towards low consumption, green and ecological, and strive to complete the creation of national green factories.

2021-12-17

Huapont was certified with <Certificate of Intellectual Property Management System>.

Our management system of intellectual property was inspected by Zhongbiaotong International Certification (Shenzhen) Co., Ltd. from December 8th to 10th. Huapont Management system of intellectual property was accredited as complying with the "GB/T 29490-2013 Enterprise Intellectual Property Management Specification". Huapont was certified with <Certificate of Intellectual Property Management System>.

2021-12-16

Huapont passed the NMPA GMP inspection for sterile preparation workshop

Chongqing Municipal Drug Administration conducted an inspection for sterile preparation workshop of Huapont on December 1st ~ 2nd in 2021. During inspection, quality related management documentations were comprehensively and deeply reviewed,